AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18076334 — intervention group
Group type: COMPARATOR
Intervention: AFP retention alone
Number of subjects: 178
Study 18076334 — intervention group
Group type: COMPARATOR
Intervention: AFP removal alone
Number of subjects: 178
Study 18076334 — intervention group
Group type: COMPARATOR
Intervention: AFP removal plus amiodarone
Number of subjects: 178
Study 17046767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedding control instruction
Number of subjects: 0
Study 17046767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12566175 — intervention group
Group type: EXPERIMENTAL
Intervention: L-365,260 30 mg
Number of subjects: 40
Study 12566175 — intervention group
Group type: EXPERIMENTAL
Intervention: L-365,260 120 mg
Number of subjects: 40
Study 12566175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10942920 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkshake preload
Number of subjects: 200
Study 10942920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendency toward overeating
Number of subjects: 200
Study 10942920 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint
Number of subjects: 200
Study 10942920 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBQ disinhibition scale
Number of subjects: 200
Study 10942920 — intervention group
Group type: EXPERIMENTAL
Intervention: TFEQ disinhibition scale
Number of subjects: 200
Study 8820894 — intervention group
Group type: EXPERIMENTAL
Intervention: isoenergetic low-carbohydrate (CHO) diet [7.8 (0.6)% total energy intake, n = 6]
Number of subjects: 11
Study 8820894 — intervention group
Group type: COMPARATOR
Intervention: isoenergetic high-CHO diet [81.5 (0.4)%, n = 5]
Number of subjects: 11
Study 8820894 — intervention group
Group type: EXPERIMENTAL
Intervention: low-CHO diet
Number of subjects: 11
Study 8820894 — intervention group
Group type: COMPARATOR
Intervention: high-CHO diet
Number of subjects: 11
Study 1579623 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 18
Study 1579623 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 18
Study 1579623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3907395 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 1.5 mg/kg b.wt.
Number of subjects: 8
Study 3907395 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 5 mg/kg b.wt.
Number of subjects: 8
Study 3907395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31740443 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of PNS (group 1)
Number of subjects: 28
Study 31740443 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks of placebo followed by 4 weeks of PNS (group 2)
Number of subjects: 28
Study 30314913 — intervention group
Group type: COMPARATOR
Intervention: two doses of 9vHPV
Number of subjects: 371
Study 30314913 — intervention group
Group type: EXPERIMENTAL
Intervention: mixed schedule of 2vHPV + 9vHPV or 9vHPV + 2vHPV
Number of subjects: 371
Study 30314913 — intervention group
Group type: EXPERIMENTAL
Intervention: 2vHPV
Number of subjects: 371
Study 30314913 — intervention group
Group type: COMPARATOR
Intervention: 9vHPV
Number of subjects: 371
Study 27622956 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic SM injection
Number of subjects: 40
Study 27622956 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 40
Study 24576885 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 with aluminum phosphate (AlPO 4)
Number of subjects: 105
Study 24576885 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 without aluminum phosphate (AlPO 4)
Number of subjects: 105
Study 24576885 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13/PPSV23
Number of subjects: 105
Study 24576885 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13/PCV13
Number of subjects: 105
Study 24576885 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13/PPSV23/PCV13
Number of subjects: 105
Study 24576885 — intervention group
Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 105
Study 22321874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle modification program
Number of subjects: 107
Study 20051587 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 200-mg tablets
Number of subjects: 0
Study 20051587 — intervention group
Group type: COMPARATOR
Intervention: tramadol IR 50-mg tablets
Number of subjects: 0
Study 18719632 — intervention group
Group type: EXPERIMENTAL
Intervention: CM3 (six capsules taken 30 min before a standardized solid meal)
Number of subjects: 19
Study 18719632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo taken 30 min before a standardized solid meal)
Number of subjects: 19
Study 15813665 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate 50/100 microg twice daily
Number of subjects: 725
Study 15813665 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg twice daily plus oral montelukast 10mg daily
Number of subjects: 725
Study 12616010 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered nitinol stent (n = 33)
Number of subjects: 68
Study 12616010 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane stent (n = 35)
Number of subjects: 68
Study 11128259 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 107
Study 11128259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithm
Number of subjects: 107
Study 11128259 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control)
Number of subjects: 107
Study 8971297 — intervention group
Group type: COMPARATOR
Intervention: 30 mg topical pharyngeal lidocaine spray
Number of subjects: 114
Study 8971297 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg topical pharyngeal lidocaine spray
Number of subjects: 114
Study 1629066 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (30 micrograms/day)
Number of subjects: 16
Study 1629066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6713905 — intervention group
Group type: EXPERIMENTAL
Intervention: chenodiol
Number of subjects: 0
Study 6713905 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29331036 — intervention group
Group type: EXPERIMENTAL
Intervention: High miR-21 expression
Number of subjects: 0
Study 29331036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PDCD4 expression
Number of subjects: 0
Study 29331036 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-21 and PDCD4 expression levels
Number of subjects: 0
Study 28500254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg BID for normal renal function, 75 mg BID for impaired renal function)
Number of subjects: 30
Study 28500254 — intervention group
Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 30
Study 28500254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 30
Study 26318836 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 243
Study 26318836 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1000 U
Number of subjects: 243
Study 26318836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 24195965 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (Philips DirectLife)
Number of subjects: 235
Study 24195965 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 235
Study 21447137 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 20
Study 21447137 — intervention group
Group type: COMPARATOR
Intervention: Lingual infiltration of 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 20
Study 21447137 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration
Number of subjects: 20
Study 21447137 — intervention group
Group type: COMPARATOR
Intervention: Lingual infiltration
Number of subjects: 20
Study 19004194 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at bilateral Hegu (LI 4) plus intravenous dripping of oxytocin
Number of subjects: 276
Study 19004194 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dripping of oxytocin
Number of subjects: 276
Study 16645295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometer (HHD)
Number of subjects: 20
Study 16645295 — intervention group
Group type: COMPARATOR
Intervention: Biodex dynamometer
Number of subjects: 20
Study 16645295 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of individuals into tertiles of muscle strength
Number of subjects: 20
Study 14520257 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 servings/day of 1% fluid milk (n=14)
Number of subjects: 28
Study 14520257 — intervention group
Group type: COMPARATOR
Intervention: Juice not fortified with calcium (n=14)
Number of subjects: 28
Study 10795744 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg QAM
Number of subjects: 243
Study 10795744 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg QAM
Number of subjects: 243
Study 10795744 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg QAM
Number of subjects: 243
Study 8699239 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C‐methionine (MET)
Number of subjects: 30
Study 8699239 — intervention group
Group type: EXPERIMENTAL
Intervention: 82Rubidium (RUB)
Number of subjects: 30
Study 1740204 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (menotropins)
Number of subjects: 67
Study 1740204 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (GnRH agonist)
Number of subjects: 67
Study 1740204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pregnancies
Number of subjects: 67
Study 6392167 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% Hexabrix
Number of subjects: 26
Study 6392167 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% Hexabrix
Number of subjects: 26
Study 6392167 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Hexabrix
Number of subjects: 26
Study 31259616 — intervention group
Group type: EXPERIMENTAL
Intervention: En masse retraction (ER)
Number of subjects: 48
Study 31259616 — intervention group
Group type: COMPARATOR
Intervention: Two-step retraction (TSR)
Number of subjects: 48
Study 29666295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound performed before spontaneous breathing trial (SBT)
Number of subjects: 250
Study 29666295 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful SBT
Number of subjects: 250
Study 29666295 — intervention group
Group type: EXPERIMENTAL
Intervention: B-pattern detected by lung ultrasound
Number of subjects: 250
Study 26344351 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy with endometrial scratch
Number of subjects: 0
Study 26344351 — intervention group
Group type: COMPARATOR
Intervention: Office hysteroscopy
Number of subjects: 0
Study 23925924 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTRA program (4 sessions of 1-hour group education, self-management, and global upper extremity exercise training, supplementing a 12-week individualized home exercise regimen)
Number of subjects: 108
Study 23925924 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 22933790 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated white matter tract strength in the premotor cortex seeded from the posterior putamen
Number of subjects: 0
Study 22933790 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated tract strength in the ventromedial prefrontal cortex seeded from the caudate
Number of subjects: 0
Study 22933790 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter density in the posterior putamen
Number of subjects: 0
Study 20137647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + surgical resection (CS group)
Number of subjects: 117
Study 20137647 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection alone (S group)
Number of subjects: 117
Study 17583029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004 survey respondents
Number of subjects: 0
Study 15129393 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise
Number of subjects: 120
Study 15129393 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing exercise
Number of subjects: 120
Study 15129393 — intervention group
Group type: COMPARATOR
Intervention: Control program (no intervention)
Number of subjects: 120
Study 11471078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid assessment protocol examining active trachoma in children
Number of subjects: 1161
Study 11471078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid assessment protocol examining trichiasis in women
Number of subjects: 1161
Study 11471078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid assessment method
Number of subjects: 1161
Study 9531580 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose IFN-alpha2b (3 MIU, 5 days/week)
Number of subjects: 195
Study 9531580 — intervention group
Group type: COMPARATOR
Intervention: hydroxyurea alone (control group)
Number of subjects: 195
Study 8554248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 400 IU in one tablet daily
Number of subjects: 2578
Study 8554248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2578
Study 2230239 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver oxide-coated urinary catheter
Number of subjects: 482
Study 2230239 — intervention group
Group type: COMPARATOR
Intervention: Control silicone catheter
Number of subjects: 482
Study 425129 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 233
Study 30862225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8 weeks)
Number of subjects: 23
Study 30862225 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 23
Study 27693438 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine for cord care
Number of subjects: 36911
Study 27693438 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 36911
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% glucose
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glucose
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sucrose
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose
Number of subjects: 560
Study 24330983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose groups (12%, 24%, 30%)
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose groups (10%, 25%, 50%)
Number of subjects: 560
Study 24330983 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation decrease
Number of subjects: 560
Study 21685798 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline co-worker social support
Number of subjects: 1240
Study 19370185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimulid (N) 100 mg 2 x/day for 20 days
Number of subjects: 60
Study 19370185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenaprost (T) 100 mg 2 x/day for 20 days
Number of subjects: 60
Study 16443872 — intervention group
Group type: EXPERIMENTAL
Intervention: Model Predictive Control (MPC) algorithm (n = 30, target range 80-110 mg/dl)
Number of subjects: 60
Study 16443872 — intervention group
Group type: EXPERIMENTAL
Intervention: Model Predictive Control (MPC) algorithm (n = 16)
Number of subjects: 60
Study 16443872 — intervention group
Group type: COMPARATOR
Intervention: Routine glucose management protocols (n = 30, control group)
Number of subjects: 60
Study 15565893 — intervention group
Group type: EXPERIMENTAL
Intervention: Medikinet-Retard (long-acting methylphenidate)
Number of subjects: 85
Study 15565893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 11780205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim stimulated donor marrow (3-4 micrograms.kg-1.d-1 for seven days prior to marrow harvest)
Number of subjects: 30
Study 11780205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim stimulated donor marrow
Number of subjects: 30
Study 11780205 — intervention group
Group type: COMPARATOR
Intervention: Control group (donors without G-CSF)
Number of subjects: 30
Study 9663838 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m., clarithromycin 250 mg b.d. and amoxycillin 500 mg b.d. (OAC)
Number of subjects: 82
Study 9663838 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.m., metronidazole 400 mg b.d. and clarithromycin 250 mg b.d. (OMC)
Number of subjects: 82
Study 1318742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine (group A)
Number of subjects: 103
Study 1318742 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, vinblastine and mitomycin (group B)
Number of subjects: 103
Study 1318742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine (group A) or Cisplatin, vinblastine and mitomycin (group B)
Number of subjects: 103
Study 2859781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 360
Study 2859781 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 360
Study 2859781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol with diuretic
Number of subjects: 360
Study 2859781 — intervention group
Group type: COMPARATOR
Intervention: Placebo with diuretic
Number of subjects: 360
Study 31584836 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network model
Number of subjects: 8956
Study 31584836 — intervention group
Group type: COMPARATOR
Intervention: Rule-based model
Number of subjects: 8956
Study 29326295 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 53
Study 29326295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27085565 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (6 months intensive exercise program under supervision)
Number of subjects: 200
Study 27085565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C intervention (1,000 mg every other day)
Number of subjects: 200
Study 27085565 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 men with normal spermogram)
Number of subjects: 200
Study 24641937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy (GFFC) + Enoxaparin (40 mg daily)
Number of subjects: 19
Study 22037124 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (1 Hz stimulation for 10 days)
Number of subjects: 7
Study 20028599 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord grape juice supplementation for 12 weeks
Number of subjects: 12
Study 17662156 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based nurse assessment of falls and fracture risk factors, home hazards, referral to appropriate community interventions, and strength and balance exercise programme.
Number of subjects: 312
Study 17662156 — intervention group
Group type: COMPARATOR
Intervention: Usual care and social visits.
Number of subjects: 312
Study 16037104 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist ganirelix daily (0.25 mg each, n = 37)
Number of subjects: 73
Study 16037104 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist ganirelix every other day (0.25 mg each, n = 36)
Number of subjects: 73
Study 12351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (group 1)
Number of subjects: 262
Study 12351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 10 mg/m(2) (group 2A)
Number of subjects: 262
Study 12351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 12 mg/m(2) (group 2B)
Number of subjects: 262
Study 12351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 262
Study 12351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 262
Study 12351376 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin (compared to daunorubicin)
Number of subjects: 262
Study 10445679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine at 0.18 microg/kg/min
Number of subjects: 20
Study 10445679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine at 0.91 microg/kg/min
Number of subjects: 20
Study 10445679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine at 2.74 microg/kg/min
Number of subjects: 20
Study 10445679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine at 5.48 microg/kg/min
Number of subjects: 20
Study 10445679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8847094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed allergen (RWA) treatment of sera
Number of subjects: 80
Study 2187700 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 50 mg b.d. p.o.
Number of subjects: 40
Study 2187700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7322785 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio feedback
Number of subjects: 48
Study 7322785 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 48
Study 7322785 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback
Number of subjects: 48
Study 7322785 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 48
Study 30711416 — intervention group
Group type: EXPERIMENTAL
Intervention: CCZ (75 mg twice daily)
Number of subjects: 24
Study 30711416 — intervention group
Group type: EXPERIMENTAL
Intervention: CCZ+RBV (1000/1200 mg daily)
Number of subjects: 24
Study 30711416 — intervention group
Group type: COMPARATOR
Intervention: CCZ+RBV
Number of subjects: 24
Study 28059912 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol injection
Number of subjects: 140